Other ErbB inhibitors, such as the EGFR inhibitor panitumumab and the dual EGFR/HER2 inhibitor lapatinib, failed to show significant clinical benefit in biliary tract cancer patients (Supplementary Table S1) [92,93]. Here, ERBB2 is linked to biliary tract cancer.